Castle biosciences stock.
Castle Biosciences, Inc. (CSTL) came out with a quarterly loss of $0.78 per share versus the Zacks Consensus Estimate of a loss of $0.91. This compares to loss of $0.25 per share a year ago.
52.55K (21.02% of Avg) 65 Day Avg: 250.03K Becton Dickinson & Co. Siemens Healthineers AG Qiagen N.V. Company & People Research & Ratings President, Chief Executive Officer & Director Franklin...Which Castle Biosciences insiders have been selling company stock? The following insiders have sold CSTL shares in the last 24 months: Daniel Bradbury ($6,274,776.69), and Derek J Maetzold ($1,265,588.97).The estimated Net Worth of Kristen M Oelschlager is at least $2.3 Million dollars as of 28 December 2022. Ms. Oelschlager owns over 7,178 units of Castle Biosciences stock worth over $1,593,448 and over the last 2 years she sold CSTL stock worth over $710,200. In addition, she makes $0 as Senior Vice President - Clinical …Texas - Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced the publication …FRIENDSWOOD - Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that new data on DecisionDx-Melanoma and DecisionDx-UM will be shared during the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place June 2-6.
Castle Biosciences (NASDAQ:CSTL) has a recorded net income of -$67.14 million. CSTL has generated -$2.84 earnings per share over the last four quarters. What is Castle Biosciences's EPS forecast for next year? Castle Biosciences's earnings are expected to grow from ($3.15) per share to ($3.00) per share in the next year.-15.00 Russell 2000 +11.96 -1.56 Gold Castle Biosciences, Inc. (CSTL) NasdaqGM - NasdaqGM Real Time Price. Currency in USD Follow 2W 10W 9M 19.88 +0.03 (+0.15%) At close: 01:00PM EST 19.88 0.00...Insiders trading at Castle Biosciences. Over the last 4 years, insiders at Castle Biosciences have traded over $369,408,068 worth of Castle Biosciences stock and bought 782,652 units worth $12,524,690 . The most active insiders traders include Daniel Bradbury, Derek J Maetzold, and Joseph C. Iii Cook.On average, Castle …
On November 3, 2023, Castle Biosciences Inc (CSTL) stock is expected to experience positive growth, according to analysts. The 8 analysts offering 12-month price forecasts for CSTL have a median target of $32.50, with a high estimate of $40.00 and a low estimate of $25.00.The estimated Net Worth of Mara G. Aspinall is at least $2.79 Million dollars as of 25 August 2022. Ms. Aspinall owns over 6,000 units of Castle Biosciences stock worth over $1,995,313 and over the last 8 years she sold CSTL stock worth over $494,800. In addition, she makes $302,714 as Independent Director at Castle Biosciences.
Key Insights Significantly high institutional ownership implies Castle Biosciences' stock price is sensitive to their...Jean Carruthers Faculty Owner/Co-Owner Founder/Co-Founder: Carruthers Instruments; Consulting Fee: Alastin Skincare, Allergan Aesthetics, Appiell, Avari, Evolus ...Castle Biosciences, Inc. is a commercial-stage dermatological cancer company, which engages in the provision of genomic information for physicians and patients. The firm offers DecisionDx-Melanoma ...Castle Biosciences is a commercial-stage diagnostics company that provides testing services for dermatological cancers. …All earnings call transcripts on Castle Biosciences, Inc. (CSTL) stock. Read or listen to the conference call. Download the investor presentation - earnings ...
Nikkei 225. 33,424.41. -0.28%. Negative. Source: LSEG - data delayed by at least 15 minutes. Get Castle Biosciences Inc (CSTL.OQ) real-time stock quotes, news, price and financial information from ...
At closing, Castle will pay $30 million in initial consideration to Cernostics security holders, which may consist entirely of cash or $20 million in cash and $10 million in common stock of Castle ...
Texas - Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced the publication of a study in the Journal of the Advanced Practitioner in Oncology (JADPRO) that assessed the viewpoints of NPs/PAs toward the clinical use of DecisionDx-Melanoma in patients diagnosed with cutaneous melanoma.Stock analysis for Castle Biosciences Inc (CSTL:NASDAQ GM) including stock price, stock chart, company news, key statistics, fundamentals and company profile.At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.559.98%. Get the latest Castle Biosciences Inc (CSTL) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment...Investing in the stock market takes a lot of courage, a lot of research, and a lot of wisdom. One of the most important steps is understanding how a stock has performed in the past. Of course, the past is not a guarantee of future performan...
Castle Biosciences Stock Forecast 11-20-2023. Forecast target price for 11-20-2023: $ 18.23. Negative dynamics for Castle Biosciences shares will prevail with possible volatility of 2.962%. Pessimistic target level: 17.92. Optimistic target level: 18.47.Innovators With A Proven Track Record of Success. An experienced team with deep expertise in discovering, developing, and commercializing diagnostic and prognostic tests. Castle Biosciences offers diagnostic tests that provide actionable, tumor-specific information for improved treatment decisions and patient outcomes. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Castle Biosciences with a $34.00 average price target, implying a 67.49% upside from current levels.Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced its financial results for the first quarter ended March 31, 2023. “Castle delivered a strong start to the year,” said Derek Maetzold, president and chief executive officer of Castle Biosciences.Dec 1, 2023 · CSTL Earnings Date and Information. Castle Biosciences last released its earnings results on November 2nd, 2023. The reported ($0.26) earnings per share for the quarter, beating the consensus estimate of ($0.92) by $0.66. The company earned $61.49 million during the quarter, compared to the consensus estimate of $44.94 million. Castle Biosciences announced that it has completed its acquisition of AltheaDx, Inc. ... up to an additional $75.0 million in cash and common stock will be payable in connection with the ...Studies have shown that using Castle’s DecisionDx®-Melanoma test to help guide the care of patients with melanoma, the deadliest form of skin cancer, improves health outcomes1-5 Castle’s...
Overview. Castle Biosciences is improving health through our innovative tests that guide patient care. For the diseases that our portfolio of tests cover, we believe the traditional approach to developing a treatment plan for cancers and other diseases using clinical and pathology factors alone is inadequate and can be improved by incorporating …
Aug 3, 2023 · Shares of Castle Biosciences ( CSTL 1.95%) were jumping 13.3% higher at 11:01 a.m. ET on Thursday. The nice gain came after the genetic testing company announced its second-quarter results ... Castle Biosciences, Inc. (the "Company") reaffirms its previously provided revenue guidance for the year ending December 31, 2023 of $170-$180 million. The Company also reaffirms its previously provided targets for the year ending December 31, 2025 relating to (i) total revenue of $255-$330 million and (ii) net operating cash flow …How much is Castle Biosciences stock worth today? ( NASDAQ: CSTL) Castle Biosciences currently has 26,910,548 outstanding shares. With Castle Biosciences stock trading at $18.06 per share, the total value of Castle Biosciences stock (market capitalization) is $486.00M. Castle Biosciences stock was originally listed at a price of …What is the target price for Castle Biosciences (CSTL) stock? The latest price target for Castle Biosciences ( NASDAQ: CSTL) was reported by Keybanc on Friday, August 4, 2023. The analyst firm set ...The primary residents of European castles during the Middle Ages were the lord and lady of the realm. These might be royalty or simply the liege lords of the district where the castle was built.Europe PMC is an archive of life sciences journal literature.Europe PMC is an archive of life sciences journal literature.Nov 27, 2023 · Castle Biosciences Stock Forecast 11-20-2023. Forecast target price for 11-20-2023: $ 18.23. Negative dynamics for Castle Biosciences shares will prevail with possible volatility of 2.962%. Pessimistic target level: 17.92. Optimistic target level: 18.47. Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced its financial results for the first quarter ended March 31, 2023. “Castle delivered a strong start to the year,” said Derek Maetzold, president and chief executive officer of Castle Biosciences.What exchange does Castle Biosciences trade on and what is the company’s stock symbol? Castle Biosciences’ stock is traded on The Nasdaq Global Market under the ticker symbol "CSTL".
In the last 3 months, 12 analysts have offered 12-month price targets for Castle Biosciences. The company has an average price target of $34.83 with a high of $41.00 and a low of $25.00.
Find real-time CSTL - Castle Biosciences Inc stock quotes, company profile, news and forecasts from CNN Business.
Belgium, a country known for its rich history, stunning architecture, and vibrant culture, offers a plethora of attractions for visitors to explore. From medieval castles to modern art galleries, Belgium has something for everyone.Europe PMC is an archive of life sciences journal literature. https://orcid.orgIn the last 3 months, 12 analysts have offered 12-month price targets for Castle Biosciences. The company has an average price target of $34.83 with a high of $41.00 and a low of $25.00.Europe PMC is an archive of life sciences journal literature.Castle Biosciences Inc. Castle Biosciences, Inc. is a commercial-stage dermatological cancer company, which engages in the provision of genomic information for physicians …Europe PMC is an archive of life sciences journal literature. https://orcid.orgCastle Biosciences Inc. Watch list Set a price target alert After Hours Last Updated: Nov 3, 2023 5:21 p.m. EDT Delayed quote $ 17.95 -0.03 -0.17% After Hours Volume: 7.02K Advanced Charting... Forecst.com predicts future values using technical analysis of a large number of analytical parameters. CSTL stock returns are also predicted based on historical data. According to our research, CSTL stock is a bad long-term investment. CSTL share price has been in a bear cycle for the past year. Castle Biosciences, Inc. stock trend is …The stock price of Castle Biosciences, a skin cancer diagnostic company, has seen a large 24% drop over the last ten trading days, while it is down 14% over the last five trading days.Castle Biosciences stock opened at $19.97 on Monday. The firm has a market capitalization of $537.39 million, a P/E ratio of -7.03 and a beta of 0.97. The company has a 50-day simple moving ...The stock price of Castle Biosciences, a skin cancer diagnostic company, has seen a large 24% drop over the last ten trading days, while it is down 14% over the last five trading days.Jun 2, 2023 · Shares of Castle Biosciences ( CSTL 0.15%) closed this week down 12.6% for the week, after being down as much as 18.3% for the week, according to data provided by S&P Global Market Intelligence ...
Castle Biosciences offers diagnostic tests that provide actionable, tumor-specific information for improved treatment decisions and patient outcomes.Tobin Juvenal CSTL stock SEC Form 4 insiders trading. Tobin has made over 5 trades of the Castle Biosciences stock since 2021, according to the Form 4 filled with the SEC. Most recently Tobin exercised 6,173 units of CSTL stock worth $14,753 on 1 March 2023.6,173 units of CSTL stock worth $14,753 on 1 March 2023.Castle Biosciences stock gains ~9% after co reports beat-and-raise Q2 SA News Tue, Aug. 09, 2022 1 Comment. Castle Biosciences GAAP EPS of -$0.06 beats by $0.70, revenue of $34.8M beats by $6.43MInstagram:https://instagram. bloomberg terminal alternativemeridian bioscience stockfarm stockarm ipo nasdaq Simply Wall St. June 8, 2023 at 3:34 AM · 3 min read. The Castle Biosciences, Inc. ( NASDAQ:CSTL) share price has fared very poorly over the last month, falling by a substantial 34%. Instead of ... what are the best sandp 500 index fundshealth care reits The estimated Net Worth of Mara G. Aspinall is at least 2.53 百万$ dollars as of 25 August 2022. Ms. Aspinall owns over 6,000 units of Castle Biosciences stock worth over 1,731,228$ and over the last 8 years she sold CSTL stock worth over 494,800$. In addition, she makes 302,714$ as Independent Director at Castle Biosciences. nasdaq akam Shares of Castle Biosciences ( CSTL 2.42%) were down more than 47% on Monday afternoon as three analysts lowered their price targets for the medical diagnostic stock. The healthcare stock is down ...Forecst.com predicts future values using technical analysis of a large number of analytical parameters. CSTL stock returns are also predicted based on historical data. According to our research, CSTL stock is a bad long-term investment. CSTL share price has been in a bear cycle for the past year. Castle Biosciences, Inc. stock trend is …FRIENDSWOOD, Texas, November 08, 2023--Castle announces data demonstrating the impact of IDgenetix® on medication response/remission rates in patients with major …